Delving into the Latest Updates on Dojin Iyaku-Kako Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

COX(Cyclooxygenases)	1

Bergenin (I) [477-90-7] had a dose dependent antisecretory effect on gastric secretion in pylorus ligated rats for 3-6 hr.The ED50 for gastric secretion in pylorus ligated rats for 6 hr was 210 mgI/kg for free acidity, 240 mgI/kg for total acidity, and 260 mgI/kg for gastric juice volumeI not only had dose dependent antiulcerogenic activities in rat stress-induced ulcers, but also had the same effect on exptl. ulcers induced by serotonin, reserpine, and fasting.The ED50, for exptl. ulcers from reserpine, serotonin, stress, and fasting were 64, 32, 38, and 38 mg/kg.

100 Deals associated with Dojin Iyaku-Kako Co., Ltd.

Login to view more data

100 Translational Medicine associated with Dojin Iyaku-Kako Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data